Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial
The Journal of Clinical Endocrinology & Metabolism · 12.07.2024 · 109 (8) · 2019-2028
DOI: 10.1210/clinem/dgae085 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.02.2024. Verfasst von Mathis Grossmann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC 3084, Australia. Hauptthemen laut MEDLINE: Quality of Life, Testosterone, Diabetes Mellitus, Type 2, Weight Loss. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Objective
To determine the effect of testosterone vs placebo treatment on health-related quality of life (HR-QOL) and psychosocial function in men without pathologic hypogonadism in the context of a lifestyle intervention. Design, Setting, Participants Secondary analysis of a 2-year randomized controlled testosterone therapy trial for prevention or reversal of newly diagnosed type 2 diabetes, enrolling men ≥ 50 years at high risk for type 2 diabetes from 6 Australian centers.
Interventions
Injectable testosterone undecanoate or matching placebo on the background of a community-based lifestyle program. Main Outcomes Self-reported measures of HR-QOL/psychosocial function.
Results
Of 1007 participants randomized into the Testosterone for Type 2 Diabetes Mellitus (T4DM) trial, 648 (64%) had complete data available for all HR-QOL/psychosocial function assessments at baseline and 2 years. Over 24 months, while most measures were not different between treatment arms, testosterone treatment, compared with placebo, improved subjective social status and sense of coherence. Baseline HR-QOL/psychosocial function measures did not predict the effect of testosterone treatment on glycemic outcomes, primary endpoints of T4DM. Irrespective of treatment allocation, larger decreases in body weight were associated with improved mental quality of life, mastery, and subjective social status. Men with better baseline physical function, greater sense of coherence, and fewer depressive symptoms experienced greater associated decreases in body weight, with similar effects on waist circumference.
Conclusion
In this diabetes prevention trial, weight loss induced by a lifestyle intervention improved HR-QOL and psychosocial function in more domains than testosterone treatment. The magnitude of weight and waist circumference reduction were predicted by baseline physical function, depressive symptomology, and sense of coherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC 3084, Australia.
- Department of Endocrinology, Austin Health, Heidelberg, VIC 3084, Australia.
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia.
- Department of Population Health, Dasman Diabetes Institute, Kuwaiit City, Kuwait.
- Department of Andrology, ANZAC Research Institute, University of Sydney and Department of Andrology, Concord Hospital, Concord, NSW 2139, Australia.
- Department of Endocrinology, Princess Alexandra Hospital and the University of Queensland, Woolloongabba, QLD 4102, Australia.
ORCID-Profile: Mathis Grossmann, David J Handelsman, Bu B Yeap, Gary A Wittert
Förderung
- National Health and Medical Research Council
Zitieren
APA
Grossmann, M., Robledo, K. P., Daniel, M., Handelsman, D. J., Inder, W. J., Stuckey, B. G. A., Yeap, B. B., Ng Tang Fui, M., Bracken, K., Allan, C. A., Jesudason, D., Zajac, J. D., & Wittert, G. A. (2024). Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 109(8), 2019-2028. https://doi.org/10.1210/clinem/dgae085
Vancouver
Grossmann M, Robledo KP, Daniel M, Handelsman DJ, Inder WJ, Stuckey BGA, et al. Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 2024;109(8):2019-2028. doi:10.1210/clinem/dgae085
BibTeX
@article{Grossmann2024,
author = {Grossmann, Mathis and Robledo, Kristy P and Daniel, Mark and Handelsman, David J and Inder, Warrick J and Stuckey, Bronwyn G A and Yeap, Bu B and Ng Tang Fui, Mark and Bracken, Karen and Allan, Carolyn A and Jesudason, David and Zajac, Jeffrey D and Wittert, Gary A},
title = {Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {8},
pages = {2019--2028},
doi = {10.1210/clinem/dgae085}
}
EUVIMED